A Urea Cycle Disorder (UCD) is a genetic disorder that results in a deficiency of some major enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the bloodstream. The urea cycle involves a series of biochemical steps in which nitrogen, a waste product of protein metabolism, is changed to a compound called urea and removed from the blood.
Normally, the area is removed from the body through the urine. In urea cycle disorders, nitrogen builds up in the blood in the form of ammonia, a highly toxic substance, resulting in hyperammonemia (elevated blood ammonia). Ammonia then reaches the brain through the blood, where it can cause irreversible brain damage, coma, and/or death. The onset and severity of urea cycle disorders are highly variable. The severity correlates with the amount of urea cycle enzyme function.
"Urea Cycle Disorders Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Urea Cycle Disorders market. A detailed picture of the Urea Cycle Disorders pipeline landscape is provided, which includes the disease overview and Urea Cycle Disorders treatment guidelines.
The assessment part of the report embraces in-depth Urea Cycle Disorders commercial assessment and clinical assessment of the Urea Cycle Disorders pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Urea Cycle Disorders collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Urea Cycle Disorders of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Urea Cycle Disorders with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Urea Cycle Disorders treatment.
- Urea Cycle Disorders key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Urea Cycle Disorders market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Urea Cycle Disorders Analytical Perspective by DelveInsight
- In-depth Urea Cycle Disorders Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Urea Cycle Disorders Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Request for sample pages: https://www.delveinsight.com/sample-request/urea-cycle-disorders-pipeline-insight
Scope of the report
- The Urea Cycle Disorders report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Urea Cycle Disorders across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Urea Cycle Disorders therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Urea Cycle Disorders research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Urea Cycle Disorders.
Table of contents:
1. Report Introduction
2. Urea Cycle Disorders
2.3. Urea Cycle Disorders Symptoms
2.6. Urea Cycle Disorders Diagnosis
2.6.1. Diagnostic Guidelines
3. Urea Cycle Disorders Current Treatment Patterns
3.1. Urea Cycle Disorders Treatment Guidelines
4. Urea Cycle Disorders - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Urea Cycle Disorders companies collaborations, Licensing, Acquisition -Deal Value Trends
126.96.36.199. Assessment Summary
4.1.2. Urea Cycle Disorders Collaboration Deals
188.8.131.52. Company-Company Collaborations (Licensing / Partnering) Analysis
184.108.40.206. Company-University Collaborations (Licensing / Partnering) Analysis
220.127.116.11. Urea Cycle Disorders Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
18.104.22.168. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
22.214.171.124. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
126.96.36.199. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
188.8.131.52. Assessment by Stage and MOA
5.1.6. Assessment by Target
184.108.40.206. Assessment by Stage and Target
6. Urea Cycle Disorders Late Stage Products (Phase-III)
7. Urea Cycle Disorders Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Urea Cycle Disorders Discontinued Products
13. Urea Cycle Disorders Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
220.127.116.11. Product Overview
18.104.22.168. Mechanism of action
13.1.2. Research and Development
22.214.171.124. Clinical Studies
13.1.3. Product Development Activities
126.96.36.199. Patent Detail
13.1.4. Tabulated Product Summary
188.8.131.52. General Description Table
Detailed information in the report?
14. Urea Cycle Disorders Key Companies
15. Urea Cycle Disorders Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Urea Cycle Disorders Unmet Needs
18. Urea Cycle Disorders Future Perspectives
19. Urea Cycle Disorders Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States